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I. Abstract  
The pharmaceutical industry presents a unique opportunity to explore the intersection 
between product innovation and the corresponding market response. The emergence of life-
enhancing drugs paired with the careful record keeping of the World Intellectual Patent 
Organization (WIPO) and the Federal Drug Administration (FDA) create a backdrop, which 
allows the relationship between announcements and firm value to be examined empirically. The 
motivational theory behind this paper stems from the efficient markets hypothesis (EMH), which 
suggests that public information such as patent application and publication would be 
incorporated efficiently in stock market returns. The relationship between R&D, stock market 
return, and patent generation is dynamic and an event study has widespread implications for 
investors and market strategists. This event-study design emulated from Fama and French’s 
(1993) three-factor model allows for direct observation of the impact central nervous system 
(CNS) pharmaceutical innovation has on firm-specific returns. This paper finds a statistically 
significant increase in returns leading up to patent application for a CNS drug for domestically-
traded firms, yet identifies a negative trend in returns surrounding the subsequent patent 
publication dates. Explained in more detail below, the decreasing returns firms experience as a 
firm’s innovation nears completion can be explained by the models used which linearly capture 
this risk and generate decreasing returns.  
 
II. Introduction 
The pharmaceutical industry is driven by innovation. With the average cost to develop a 
new drug hovering around $800 million (Grabowski et. Al 2002), pharmaceutical research and 
development (R&D) holds 19% of all business spending on R&D (Ding 2014). This intersection 
between innovation and announcements provides an empirical opportunity to examine not only 
the impact of innovation on a firm’s value, but on the validity of the efficient markets hypothesis. 
Given that the backbone of the pharmaceutical industry is intellectual property, this paper 
examines: how does CNS pharmaceutical innovation impact a firm’s value? This paper studies 
the significance of announcement effects in stock price volatility when pharmaceutical 
companies request and publish patents on active ingredients in major antidepressant, 
antipsychotic, and anxiolytic drugs in light of EMH. Such an examination of announcement 
effects has never been done for patent application and publication dates, though Sharma and 
Lacey (2004) examined such effects surrounding FDA approval dates. I also extend my analysis 
to include FDA approval dates as a marker of external validity. This new question is interesting 
Sprague, K.  
! 3 
and relevant both for investors, marketing strategists, and pharmaceutical researchers and 
developers. Because innovation signals progress regardless of outcome, investors could track and 
utilize patent announcements as an investing tool and a positive market signal that may be 
extended to other industries. On the firm side, marketers could time such events with strategic 
publicity to maximize firm profits and capitalize on firm value increases.  
This paper defines an “announcement” as a firm-specific event or action that changes 
public knowledge of a firm by potentially increasing or decreasing a firm’s value. Similarly, this 
paper defines an “innovation” as an entirely new CNS pharmaceutical drug. This paper examines 
the idea that the efficient markets hypothesis is false surrounding three types of announcements: 
patent application date, patent publication date, and FDA approval date of the innovations 
defined above. It seeks to disprove the idea that this information is already efficiently 
incorporated into security prices. Assuming an efficient market however, price on such event 
dates should only increase on the event date. However, assuming an inefficient market, security 
price should slowly increase beginning on event dates as information shifts from private to 
public knowledge.  
Note that there are distinct times at which price changes may be expected. First is the 
discovery date, which corresponds to when a firm first applied for a patent via the World 
Intellectual Property Organization (WIPO), which this paper calls the application date.  Second 
is the patent publication date, when the patent office releases information about the application. 
Third is the date of the Federal Drug Administration (FDA) approval. These distinct times are 
classified as announcements by this paper.  
According to the United States Patent and Trademark Office, a member of the public 
cannot obtain “direct physical access” to pending applications, but can obtain them online, by 
mail, etc. (USPTO.gov). Because this is difficult for the uninformed member of the public, and 
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given that firms do not “announce” pending applications as they may negatively affect a firm’s 
value if left unpublished, I expect that patent applications as announcements will have no effect 
on a firm’s security price, thereby leaving no room for investor profit. Stock price will already 
have incorporated this information by insiders at the time of the event. However, I expect there 
to be a significant price change around patent publication and FDA approval dates. Literature 
surrounding FDA approvals can be inconsistent, but that of drug development via patents might 
provide more reassuring and significant social effects, which is the central focus of this paper. 
This paper proceeds by examining the wide variety of literature in this field beginning 
with an overview of EMH and its validity as an event-analysis tool, extending EMH to the 
pharmaceutical industry by delving into drug development as an announcement and potential 
signal to investors, and finally on patenting an the financial implications of innovation. 
Following the literature review, the paper is organized as follows: an overview of data sources 
and compilation techniques, regression and analysis methodology, results, and finally a 
conclusion. 
III. Literature Review 
i) EMH and Reaction to News 
A market in which prices at all times completely reflect all available information is 
efficient (Fama 1970).  The strong form of EMH suggests that all information, public or private 
is reflected in market prices, while the semi-strong form states that only public information is 
incorporated into prices. The weak form of the EMH suggests that only previous market 
information such as interest rate is reflected in security price. Stated more directly in Section VI, 
this paper tests the strong form of the EMH, which would result in no net price change 
surrounding events. In their technical analysis, Rehman and Khidmat (2013) justify EMH by 
stating that all public information (characteristic of the weak EMH form) is reflected in the listed 
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stock price. The stock market overreaction hypothesis, however, challenges EMH, stating that 
unanticipated news or innovations leads to potentially benefiting, exaggerated trends that 
eventually correct themselves (Gregoriou 2010). Due to the wide variety of complex, sector-
based information surrounding the factors comprising a stock price, prediction of stock volatility 
is difficult. Rehman and Khidmat (2013) examine the multitude of financial indicators that 
determine security price, while Eizaguirre et al. (2009) find that changes in volatility are 
directionally heterogeneous based on sector and location.  
 There is no question that new products and announcements have widespread economic 
effects. However, the magnitude and direction of announcement effects have been studied to 
various degrees, generally finding consistent and intuitive results. Beaver (1968) first uncovered 
that positive earnings announcements increase share prices, a finding that has been confirmed 
and studied further. Savor and Wilson (2013) similarly find that the average announcement-day 
excess returns from 1958 to 2009 was 11.4 basis points compared to 1.1 basis points for other 
days. Chaney et al. (1991) also found a small increase in stock price during the three days 
surrounding the announcement, and Flannery and Protopapadakis (2002) similarly find an 
announcement effect on returns from announcement news sensitivity by looking at volatility of 
various shocks.  
While Flannery and Protopapadakis (2002) focus on announcement news, Savor and 
Wilson (2013) look at expected returns, a more relevant subject for investors requiring 
compensation for their risk-bearing behavior. They find positive expected returns of 
announcement effects stemming from news about inflation, unemployment, or interest rates, 
while most other literature focuses on innovative news or technological advancements. Sharma 
and Lacey (2004) find a significant effect in stock volatility in a three-day window surrounding 
innovative announcements, though no effect was found outside the event window. This result 
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empirically demonstrates that unanticipated positive news is eventually incorporated efficiently 
into stock prices, a result consistent with weak EMH, given a subsequent time lag.  
Other announcement analyses, such as Rodriguez and Valcarcel (2012), find that the 
impact of negative news items on stock prices is larger than positive news items. Positive 
product announcements are indicative of true firm innovations, which face little to no 
competition and allow firms to obtain high profits when that information becomes public. While 
a positive profit margin is likely to disappear, it still provides an incentive for firms to create 
sustainable growth through continued product innovation.  
Studies that analyze the effect of innovation in light of the EMH give mixed results. Eddy 
and Saunders (1980), find no effect of new product announcements on monthly stock returns, 
while Wooldridge and Snow (1990) find a positive reaction to product news that quickly declines 
after a ten-day window. These varied results suggest that information is either absorbed more 
quickly than imagined, favoring the strong form of the EMH, or that markets ignore some 
information. Regardless, the effects are difficult to isolate across industries. In the interest of 
maintaining consistency with previous literature, this paper also has an intra-industry focus in the 
pharmaceutical industry. 
ii) The Pharmaceutical Industry Intro: Development and R&D Intensity  
Competition and innovation in the pharmaceutical industry hinges on technological 
progress, and progress in the form of innovative drugs can increase life expectancy and quality of 
life. The pressure to innovate is paired with a complex development process that usually takes 
about fifteen years—from drug discovery to FDA approval—making development trends 
somewhat difficult to track (Ding 2014). There is vast literature that studies innovation, some of 
which concentrate on Central Nervous System (CNS) drugs due to their arguable classification 
as luxury goods from a public health perspective. CNS drugs are likely to cause a market effect 
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because innovation and technological advancement are strong indicators for beneficial 
investments and sustained growth (Duggan and Goyal 2012). CNS drugs act on the brain and 
spinal cord and include the therapeutic drug classes that make up the dataset for this study: 
antidepressants, antipsychotics, and anxiolytics. Drugs in this category have high technological 
advancement and comparative effectiveness, as defined by Morgan et. al (2008), which makes 
them key components of the innovation effects on the market and an interesting indicator for 
innovative analysis. 
The drug development process is extremely complex and highly regulated. As mandated 
by the FDA, clinical trials occur in multiple stages as long as 14 years after the synthesis of a 
new compound (DiMasi 2001). Only two statistically significant positive trials are needed to 
obtain drug approval and many companies hide countless negative trials leading to more 
expensive drug development and a positive publishing bias (Kirsch 2010).   
Due to the high level of technological advancement, development of drugs such as 
antipsychotics or antidepressants require large investments in R&D. Grabowski et al. (2002) 
estimates that the average cost of developing a new drug is about $800 million. Civan and 
Maloney (2006) show that global pharmaceutical companies adjust their R&D priorities 
according to prevalent diseases in the United States, and Whittaker’s survey (2005) pinpoints an 
astonishing increase in severe mental illness in the United States over the past fifty years. 
Pharmaceutical R&D holds 19% of all business spending on R&D (Ding 2014), yet research and 
development of innovative pharmaceuticals is risky and uncertain, so high R&D costs must be 
offset by revenue potential (Heible 2013). Rosiello and Orsengio (2008) find that the clustering 
of biotech companies is driven by resource funding allocations and can lead to vertical 
integration, where a majority of innovation comes from only within-cluster and could prevent 
market entry. 
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Because of the strong focus on innovation and the high allocation of funds to R&D, the 
pharmaceutical industry is ideal for empirical research on stock price overreaction as new 
products signal increasing internal capabilities to innovate according to Geroski et. al (1993).  
Sharma and Lacey (2004) empirically examine whether product development pays and find 
results consistent with the efficient market hypothesis: that the market responds to FDA approval 
of a drug positively. They analyzed the effects of new products on firm value by using an event 
study methodology described in Section VI. Rodriguez and Valcarcel (2012) results contrast this 
by using an ARMA-GARCH dynamic economic model to detect large price changes in stock 
prices in the seventeen largest pharmaceutical firms and find that only 10 of 1721 FDA 
approvals of new drugs were related to abnormally large returns. The difference in results stems 
from Rodriguez and Valcarcel’s (2012) finding that the market responded more severely to 
negative news items; unlike Sharma and Lacey (2004), they focused not on FDA approval dates, 
but on the R&D process, where there is a high probability that a drug will be rejected in clinical 
trials.   
iii) Pharmaceutical Patenting and Financial Implications of Innovation 
 Because patenting is the backbone of innovative intellectual property, patent protection 
can serve as a firm performance indicator.  It is worth noting that a World Bank survey showed 
that intellectual property protection was a central factor in global investment decisions in 
pharmaceuticals (Santoro and Gorrie 2005). Pakes (1985) claims that the number of successful 
patent applications is a measure of the firm’s investment in incentive activity (new product 
development projects) and can act as an indicator of output through the stock market’s firm 
valuation. The patent is a more direct valuation of successful research than other performance 
indicators. Duggan and Goyal (2012) find that there are heterogeneous effects on retail drug 
prices by type of pharmaceutical product patent, specifically those claiming the active ingredient.   
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 Golec et al. (2010) extends one innovation concern by linking stock prices to future R&D 
spending, and finds that price regulation such as the Health Security Act had a negative effect on 
stock prices and firm R&D spending. Lee and Chen (2009) also find a negative effect on 
shareholder value related to firm size, demonstrating that amount allocated to investment is 
impactful in investor signaling. Delving deeper into the effect on research and development 
effects, Berk, Green, and Naik (2004) examine the return dynamics of new technologies and find 
that there is extensive uncertainty embedded in research and development projects; this risk 
potentially diminishes potential profitability after technical progress. Sharma and Lacey (2004) 
suggest that it may be beneficial for firms to refrain from hyping new products due to the large 
effect of negative information on the financial markets. However, by focusing on positive 
product innovation, this paper aims to avoid the asymmetrical response to new product 
development. One potential bias worth noting is that positive product innovation analysis might 
not necessarily capture the complete valuation of a pharmaceutical firm.  
 While various techniques have been used as analysis tools in innovation event studies, 
this paper emulates the Fama-French (1993) model as an expansion of the Capital Asset Pricing 
Model to explain the announcement effects in pharmaceutical innovation. Brown and Warner 
(1985) conclude that the characteristics of daily stock return data presents few difficulties for 
event studies and find that simple methodology based on the market model is well specified and 
powerful under many conditions. Given this, CAPM provides a baseline to examine the effect of 
the patent and FDA announcements.  
iv).  CAPM Methodology and Background 
The Capital Asset Pricing Model (CAPM) was used first to estimate market parameters 
alpha and beta and is widely considered to account for 70% of stock price volatility (Corrado 
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2010). Developed in the early 1960s by William Sharpe (1964), Jack Treynor (1962), John 
Lintner (1965) and Jan Mossin (1966), for any firm-specific security i at time t, the model is as 
follows: (Rit –Rt)= α + β(Rmt-Rf) + εit,. CAPM allows expected rate of return to be calculated for 
an asset and was used in this paper as a baseline to maintain consistency with existing financial 
literature. Here, (Rmt –Rf ) is a market portfolio that takes the value weight of all firms 
incorporated in the US and listed on the NYSE, AMEX or NASDAQ that have a CRSP (Center 
for Research on Security Prices) share code of 10 or 11 at the beginning of month t. Rf,, the one 
month treasury bill rate, or the risk-free rate, is subtracted from Rm. εit is the error term, and β is 
systematic risk. CAPM suggests that an investor’s equity cost is determined by beta.  
 v) The Fama-French Model 
The Fama-French (1993) three-factor model, an expansion of CAPM, which primarily 
estimated beta, was used to determine what was driving the returns. The Fama-French model 
estimates market parameters which include Rm-Rf , SMB (the small market capitalization minus 
big), and HML (high book to market ratio minus low). SMB is a covariate that takes into account 
size, or the extra risk associated with small company (cap) stocks. Small-cap stocks tend to 
generate higher returns than large-cap stocks in the long run, though this comes with higher risk. 
HML is a covariate that accounts for the value of owning stocks that have been undervalued and 
tend to generate higher returns than growth stocks in the long run. This model expands on the 
capital asset pricing model by adding the two factors, SMB and HML, and explains 90%-95% of 
the variability in returns (Corrado 2010).  Data were gathered from Kenneth French’s online 
database and use six value portfolios formed on size and book to market by the Center for 
Research on Security Price.  This dataset incorporates all firms listed on NYSE, AMEX, and 
NASDAQ from July 1, 1926 to December 31, 2014.  The model is estimated as follows:  
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Rit -Rf= α + β1(Rmt-Rf) + β2SMB +β3HML  +β4 1(dayafter)+ εit 
The model includes a dummy variable called ‘dayafter’ which estimates the difference in returns 
one day after the event date. Regressional outputs depicted in the appendices display the variety 
of event window indicator variables used. Molecule fixed effects were included to allow for 
within-molecule variation observation.  SMB was calculated as the average return on three small 
portfolios minus the average return on three large portfolios. HML was calculated as the average 
return on the two value portfolios minus the average of the two growth portfolios.  
 
SMB =[ ⅓ (small value + small neutral + small growth) - ⅓(large value + large neutral + large growth)] 
 
HML = [½ (small value + big value) - ½(small growth + big growth)] 
 
The inclusion of these variables by Fama and French (1992,93) separates stock returns 
into three distinct risk factors: beta (the brainchild of CAPM), size (which takes into account the 
extra risk in small stocks and the potentially higher returns), as well as value (which takes into 
account companies that have lower market values compared to intrinsic value). Berk, Naik, and 
Green (1999) validate this book-to market approach used by Fama and French, and explicitly 
state in their model development of expected security returns that this variable (used in the 
generation of SMB and HML) appears to justify the fluctuation in a firm’s risk. 
In his 2002 critique, Griffin finds that the Fama-French three factors are country-specific 
and concluded that the model performs best when localized within-country. Due to this, this 
paper focuses primarily on domestically traded public firms, though an international extension 
can be found in Appendix 3.  
Sprague, K.  
! 12 
The vast and varied literature linking R&D to firm security price only highlights the 
importance of understanding the market structure of this industry through announcement effects. 
I expand on the above literature by using the Fama-French model to examine the effect of 
announcements on firms in one extremely dynamic industry. Examining announcement effects in 
pharmaceuticals will increase understanding of the mechanisms in which innovation contributes 
to both economic growth and firm value. 
IV. Data Sources and Compilation Techniques 1 
Data were compiled as three different panel datasets surrounding the three different 
announcement dates: patent application, patent publication, and FDA approval date. Each panel 
dataset included all innovative antidepressant, antipsychotic and anxiolytic drugs beginning in 
1974 and spanning twelve different domestic pharmaceutical companies traded on either NYSE 
or NASDAQ. The multi-dimensional panel data contains molecule, company, and exchange 
differences occurring through time.  Within-molecule and variation is the primary interest of this 
paper as molecules are perfectly collinear with a pharmaceutical firm due to the nature of a 
patent giving exclusive rights to one firm. However, biotech clustering and the intensive cost of 
R&D forces mostly large companies to innovate and innovate frequently, making the molecule, 
and not firm the relevant observation.   
Like Duggan and Goyal (2012), CNS molecules were the pharmaceuticals of interest and 
were compiled into a list of three therapeutic drug classes—antidepressants, antipsychotics, and 
anxiolytic molecules from the FDA Orangebook2 and the RxList3.  To ensure econometric 
accuracy, assume there is no selection bias; molecules were selected as a complete list of 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!1!In order to ensure accuracy and robustness of the date, I sought help from professional librarian Jennie Gerke at the 
University of Colorado at Boulder.  She is the Head of the William M. White Buiness Library.  
2 http://www.accessdata.fda.gov/scripts/cder/ob/ 
3 http://www.rxlist.com/script/main/hp.asp 
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innovative CNS molecules to ensure accuracy of the sample.  Molecules that were excluded were 
randomly dropped as a result of insufficient or lack data. Proper randomization was achieved by 
allowing each molecule to have the potential to be included in the compiled panel datasets.  
Molecules that have been taken off the market were dropped. Non-innovative molecules, or 
molecules that lack a new neurological mechanism or were chemical, generic variants, were not 
included in the dataset. Patent application date, publication date, and innovator company were 
obtained from the World Intellectual Patent Organization (WIPO)4 for each innovative molecule 
and this data was crosschecked against information from Google Patent5. Daily stock price 
closing data were gathered and matched to molecule and innovator company through 
Yahoo!Finance6 historical pricing. If stock data were not available on Yahoo!Finance, then data 
were obtained from the ThomsonOne online database. Molecules patented by private companies 
with no historical stock price data were dropped. If historical stock price data for a firm were not 
available for the corresponding patenting dates, those observations were dropped. Molecules 
patented by companies that later were acquired by larger firms were also dropped because the 
larger firms historical stock prices would not have reflected the smaller firm’s value accurately 
during the time of the announcement. Shown below is a descriptive table of the data separated 
first by announcement date and then by both drug class and firm type. 
 
 
 
 
 
 !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
4 http://www.wipo.int/portal/en/index.html 
5 https://www.google.com/?tbm=pts&gws_rd=ssl 
6 http://finance.yahoo.com 
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Table 1: Summary Statistics 
 
If a molecule was patented by an international company and not traded domestically on 
NYSE or NASDAQ, stock prices were converted to U.S. dollars using matched historical 
exchange rate data changing through time and added as a second tier of analysis for robustness. 
This second tier of analysis added ten innovative molecules from nine different international 
firms on five different exchanges shown below. As stated above, the inclusion of international 
firms, as found by Griffin (2002) may have biased the regressional analysis and was therefore 
solely included in Appendix 3 as an extension for completeness and robustness. Table 2, below, 
shows international firms with innovative molecules that were included in the analysis of 
Appendix 3.  
 
 
 
Events       Total 
Application Date 
CNS Drug Class 
Antidepressants 27 
44  Molecules Antidepressants 12 
Anxiolytics 5 
Pharma Firms 
Domestic 12 
21 Firms 
International 9 
Publication Date 
CNS Drug Class 
Antidepressants 28 
46  Molecules Antipsychotics 13 
Anxiolytics 5 
Pharma Firms 
Domestic 12 
21 Firms 
International 9 
FDA Approval Date 
CNS Drug Class 
Antidepressants 5 
10 Molecules Antipsychotics 4 
Anxiolytics 1 
Pharma Firms Domestic 7 7 Firms 
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Table 2: Internationally-traded firms with innovative molecules 
 
To maintain consistency with existing financial literature, the Fama-French daily factors 
were gathered for inclusion in the Fama-French three factor model: SMB, HML, and Rm-Rf. 
These were obtained from Kenneth R. French’s Online Data Library7 and are calculated as 
outlined above in the review of literature.  
A variable called ‘time index’ allowed for stock return data to be compiled as a panel and 
ranges from -250 to +14, equaling zero on the announcement date. Indicator variables were 
generated to observe an effect on returns for specified periods. For example, the indicator 
variable ‘twoweeksbefore’ takes the value one for return data in the pre-event window, when 
‘timeindex’ = -14 to 0.  Indicator variable ‘dayafter’ takes the value one only when ‘timeindex’= 
+1.  
Generally, patent event windows surrounding the outlined announcement dates did not 
overlap, which allowed estimations for parameters of the normal return model to not be 
influenced by other patent announcements. However, due to the nature of the panel data 
compiled and used in this paper, a dummy variable was introduced in order to eliminate 
innovative molecules introduced by the same company in the overlapping event window in the 
patent application announcement dataset. Due to this restriction and in order to reduce this noise, 
five innovative molecules in the application date panel have smaller historical windows and two 
innovative molecules were entirely dropped as their event dates perfectly overlapped. !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
7 http://mba.tuck.dartmouth.edu/pages/faculty/ken.french/index.html 
Firm  PARS FQX NEUR AKZOY HLUYY HES XANO CORX RHHVF 
Exchange OTCMKTS DU CPH OTCMKTS OTCMKTS AMS B.ST OTCMKTS OTCMKTS 
Currency USD EUR DKK USD USD EUR SEK USD USD 
Molecule  1 1 1 2 1 1 1 1 1 
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To observe further differences across time, a variable called ‘quarterly time trend’ was 
introduced and takes the value one through four depending on the business quarter in which the 
patent announcement or FDA approval occurred. This variable was thought to observe seasonal 
differences in pharmaceutical innovation trends.  
V. Pitfalls and Biases of Data Collection 
One pitfall of solely focusing on pharmaceutical innovation is that innovator companies 
potentially sell published patents, so there is a lack of consistency in data matching with FDA 
approval date. This led to a much smaller panel dataset surrounding FDA approval date and 
therefore less econometric power.  Secondly, many drugs in this class are widely used in Europe 
and Asia, but not approved by the FDA in the US, yielding an even smaller FDA approval 
dataset.  
It is also important to note the high failure rate of pharmaceuticals during the clinical trial 
period (Fernandez and Huie 2007). Despite this, the effect of patent application may signal to 
investors that a pharmaceutical firm is entrepreneurial, innovative, and worth investing in due to 
the strong research and development initiatives. The theory behind this paper suggests that an 
innovation signals to investors that a firm is growing. Because innovation is necessary for 
sustained growth and is a trial and error process by nature, successful or even unsuccessful 
innovations should positively increase a firms value as seen in an increase in stock price. 
Unsuccessful new ventures still display an entrepreneurial, profit-oriented firm that investors are 
likely to demand. 
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VI. Methods  
The following hypothesis is examined both assuming efficiency and inefficiency. The 
corresponding diagrams outline the expected price change. 
H0: There will be no net price change surrounding the 
announcement of a patent, as “new” information is 
already efficiently incorporated into security prices in 
the strong model via insider trading or other 
information leakage. 
 
 
 
 
H1(Assuming efficiency): Because the market is 
efficient, prices quickly spike surrounding 
announcements before obtaining a new equilibrium 
price. Therefore, there is only room for investor 
profit contingent on patent publication or other 
information right on the announcement date. In this 
weak form of the efficient markets hypothesis, 
security value will change when privately held 
information becomes public. 
 
 
H2 (Assuming inefficiency): Because the market is 
inefficient, prices will slowly increase following the 
event date as the information becomes publicly 
known, leaving room for investor profit. 
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 Shown below, Figure 1 depicts the three-day annualized average returns (Rit) of 
domestically-traded firms surrounding application date, while Figure 2 similarly depicts Rit 
surrounding patent publication date. A general trend of increasing returns following the event 
date is observed.   !
Figure 1 
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!
Figure 2 !!
i).  Event Study Methodology 
My event study methodology is emulated from Sharma and Lacey’s (2004) event study 
on product development outcomes and firm valuation. A 236 day period was used to estimate 
market parameters (-250 to -14) and a 29 day event period included the event window (day -1, 0, 
and +1), a pre-announcement window comprised of two weeks of daily returns (-14 to -2) to 
check for information leaks, and a post-announcement window (+2 to +14) to demonstrate 
persistence.  This event study methodology allows annualized daily returns for security i to be 
linearly estimated to returns on the market portfolio and maintains consistency with financial 
literature that examines announcement effects. 
Daily historical stock price data was gathered from Yahoo!Finance historical pricing and 
ThomsonOne, and returns were calculated as follows where Pit is the percentage change in stock 
price (P) for firm i at time t. 
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Rit =(Rt-1- Rt)/Rt, 
The following depicts the calculation performed to annualize Rit where 250 is the average 
number of stock trading days per year (Sharma and Lacey 2004) and Rf is the risk-free daily 
treasury bill rate acquired from the Federal Reserve.  
Rit-Rf: (1+Pit)250-1 - Rf 
   
The multi-layered tiered regressional analysis this paper uses can be observed in Figure 
3, which outlines the various regressions performed for the three specific event dates using both 
the CAPM and the Fama-French Model and various indicator variables included. !
 
Figure 3:  Tiered Regressional Analysis   
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ii). Specification of empirical design to estimate the Capital Assets Pricing Model (CAPM) 
and the Fama-French Model extension is as follows:  
 
To examine the impact of announcements on the value of a firm’s equity, it is necessary 
to posit a relationship between information and a price increase. (MacKinlay 1997).  
This paper maintains general conditions under which ordinary least squares (OLS) accurately 
estimates both CAPM and the Fama-French Model. Under the following assumptions, OLS can 
be considered efficient. Both models assume that asset returns are jointly and multi-variately 
normal and are independently distributed through time. By assuming a normal distribution, both 
models can be correctly specified.  
The gain from extending analysis to the Fama and French’s three-factor model allow for 
the restrictions and biases of the CAPM to be eliminated and increase the explanatory power of 
the model. Though CAPM is linearly estimated and follows the assumed joint normality of 
returns, biases of CAPM include the disequilibrium of present value and it’s central focus on 
risk.  These biases ignore other factors that contribute to the variation in returns such as size and 
value. Fama and French (1996) postulate that beta alone cannot explain expected returns. 
CAPM removes the portion of the return related to variation in the market return that 
reduces the variance of the abnormal return. Fama and French use a different asset pricing theory 
that combines other risk factors in a linear fashion.  Fama and French (1992) state that 
performance of portfolios can be evaluated by comparing returns with returns of benchmark 
portfolios with similar book-to-market equity characteristics. Malin (2004) states that the CAPM 
alone is not sufficient to describe the variation in equity returns and argues that the performance 
should be evaluated using the multifactor model. 
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VII. Results and Discussion 
i) Effect on Patent Application Announcement Date 
Appendix 1 illustrates regressional outputs for seven indicator variables surrounding 
patent application and publication date for domestic firms in the CAPM model. Two weeks 
before and the day before show statistically significant increases in returns surrounding 
application date (in Table 1.1): 78.94% and 269.88% annualized increases respectively. 
Similarly, we observe a 142.46% increase in during five day window. Extending the analysis to 
include covariates SMB and HML increases the model’s R-squared value and therefore the 
model’s fit. In Table 2.1, we see 78.5% increase in annualized returns in the two weeks before 
patent application date and a 268.45% increase in returns on the day before application date. This 
effect in the Fama and French’s model of domestically-traded firms surrounding patent 
application date allows us to reject the null hypothesis (which states that the market is efficient 
and already incorporates public and private information, thereby displaying no increase in 
returns) in favor of alternative hypothesis two which demonstrates a slower, inefficient price 
increase leading to this patent announcement date. The significance of the five-day window 
demonstrates this persistent returns increase even slightly after the event date. 
ii) Effect on Patent Publication Announcement Date 
Table 1.2 portrays negative statistically significant returns during the two weeks before 
patent publication date and on the patent publication date using the CAPM. We see a statistically 
significant decrease of 197.46% in the two weeks leading up to patent publication and an even 
more dramatic decrease of 671.87% on the event date. Table 2.2 similarly includes Fama and 
French’s factors SMB and HML to observe effects surrounding publication dates, yet depicts 
statistically significant decreasing effect on returns is still observed both two weeks before and 
Sprague, K.  
! 23 
on the patent publication date. This effect can be explained by a phenomenon discovered by 
Berk, Naik, and Green in their 2004 analysis, mentioned in the above review of literature. 
 Berk, Naik, and Green (2004) identify a CAPM relationship that explains the decreasing 
risk of a new venture over time. In the case of patent publication date, the large negative returns 
signal the decreasing risk, therefore decreasing returns of the CNS pharmaceutical innovation. 
Systematic risk is highest early in the stages of new ventures, which may explain the positive, 
significant coefficients during patent application date, where there is a much higher failure rate. 
Berk, Naik, and Green (2004) find specific times that leave a new venture more vulnerable to 
information about technological progress, and other times less so.  
iii) Effect of Other Covariates  
The statistically significant and positive ‘overlap’ indicator variable allows us to 
conclude that frequently-innovating companies show consistently higher returns across the entire 
event window than companies that only possess one innovative molecule in this dataset.   
‘Quarterly time trend’ allows for some seasonality to be observed. Across the domestic 
datasets, the indicator variable is statistically significant, large, and negative, meaning that 
returns diminish in later business quarters.  Both statistically significant variables ‘quarterly time 
trend’ and ‘overlap’ introduce heterogeneous effects on pharmaceutical innovation timing and 
frequency, respectively, nd  require further research to more concretely define timing trends of 
such announcements. 
Rm-Rf is a variable that accounts for systematic risk relative to the market. Across 
primary patent application datasets, this variable is negative, meaning that securities i are less 
risky relative to the market.  In primary patent publication datasets, however, this variable is 
positive, showing more risk relative to the market.  
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SMB is a usually positive variable that controls for size. However, in this analysis, large 
companies are only included due to the earlier discussed effect of biotech clustering causing a 
“small firm effect” in which smaller firms tend to outperform larger ones. In the case of patent  
publication, large firms seem to be discounted due to inefficiency and high costs. HML accounts 
for the spread. This is positive because all companies included are value stocks, not unknown 
growth companies. The data show that portfolio returns can be accredited to this premium and 
therefore coefficients for HML are largely negative.  
 It is important to note that the lack of statistical significance in covariates Rm-Rf, SMB, 
and HML in multiple tables result from the small sample size and therefore lack of economical 
power, particularly in the CAPM and dataset that extends the analysis to FDA approval dates. 
iv) International Extension 
Appendix 3 depicts an international extension of analysis surrounding patent application 
and publication dates using both the CAPM and the Fama-French model. The effect of the 
pharmaceutical announcements are inconsistent with the domestic analysis of pharmaceutical 
firms, yielding significant negative coefficients on both patent application and publication date, 
which thus validates Griffin’s finding (2004) that the CAPM and Fama and French’s model 
perform optimally when localized.  
v) FDA Approval Extension 
Appendix 4 shows that the effect of FDA approval of a CNS drug on a firm’s returns is 
not statistically significant. However, it is worth noting that negative coefficients can be 
observed for all event indicator windows, except on the announcement date, signaling positive 
returns as a result of such approval. This finding is consistent with other literature (Sharma and 
Lacey 2004). 
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VIII. Implications and Conclusion 
 This paper examined the significance of announcement effects when pharmaceutical 
companies request and publish patents on active ingredients in major antidepressant and 
antipsychotic drugs by looking at the daily stock prices surrounding various pharmaceutical 
announcements. Significant increases in returns were observed in the pre-event window leading 
up to a drug’s application date. This result allows us to reject the null hypothesis that private and 
public information is already incorporated in a firm’s security price. In the case of patent 
application date for CNS pharmaceuticals, the market is inefficient and returns fluctuate as a 
result of new information.  
Patent publication announcements yield decreasing returns in the pre-event window.  
This validates the CAPM relationship identified by Berk, Naik, and Green (2004), who outline 
the decreasing risk new technologies experience as they approach completion, thereby 
simultaneously exhibiting decreasing returns. In the case of pharmaceutical patent publication 
date for CNS innovations, the null hypothesis that the market is strongly efficient cannot be 
rejected.  
 Despite heterogeneous and unexpected results, Figure 1 and Figure 2 in Section VI 
illustrate extreme volatility surrounding pharmaceutical patent announcement dates that demand 
research extensions. Such research extensions could include widening the data scope to other 
therapeutic classes of innovative pharmaceuticals and expanding the analysis to other event 
dates, furthering the implications of this paper. Implications stemming from innovative 
announcement studies such as this paper are extremely critical for investor strategy; 
pharmaceutical investors could more closely watch the pharmaceutical development process and 
invest money in companies that allocate more money to R&D as specific firms near patent 
application dates. Market strategists can also benefit from the findings of this paper by 
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potentially altering or protecting patent application announcements to ultimately maximize 
profits.  
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Appendix 1. Capital Asset Pricing Model: Domestic Firms 
! !
Table 1.1: Effect of Patent Application on Firms' Daily Annualized Returns 
Domestic Firms Traded on NYSE or NASDAQ: CAPM 
 
(1) (2) (3) (4) (5) (6) (7) 
Rm-Rf -7.40 -7.32 -7.36 -8.00 -9.00 -7.91 -8.18 
 
[9.29] [9.29] [9.29] [9.28] [9.03] [9.27] [9.25] 
SMB - - - - - - - 
        HML - - - - - - - 
        Two Weeks Before 78.94 
      Day Before [39.87]** 269.88 
     Day 
 
[158.25]* -19.25 
    Day After 
  
[131.33] 104.51 
   Two Weeks After 
   
[151.30] 38.83 
  Three Day Window 
    
[40.02] 117.17 
 Five Day Window 
     
[86.13] 142.87 
       
[69.47]** 
Overlap 251.03 174.95 176.33 177.59 160.03 176.40 181.73 
 
[101.42]** [93.95]* [94.06]* [93.91]* [92.45]* [93.81]* [93.78]* 
        Quarterly Time Trend -169.67 -168.13 -168.13 -167.53 -168.42 -167.52 -167.89 
 
[72.06]** [72.08]** [[72.08]** [72.11]** [71.99]** [72.12]** [72.05]** 
        Constant 1263.86 1262.86 1264.04 1267.08 1260.39 1266.09 1267.13 
 
[221.58]*** [221.69]*** [221.67]*** [221.78]*** [221.04]*** [221.79]*** [221.58]*** 
Molecule FE Yes Yes Yes Yes Yes Yes Yes 
        Observations 7978 7978 7978 8009 8412 8009 8040 
R-squared 0.0390 0.0389 0.0385 0.0384 0.0391 0.0386 0.0389 
Robust standard errors in brackets, clustered by molecule,  
***significant at 10%; **significant at 5%; *significant at1% 
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Table 1.2: Effect of Patent Publication on Firms' Daily Annualized Returns 
 
Domestic Firms Traded on NYSE or NASDAQ: CAPM 
 
(1) (2) (3) (4) (5) (6) (7) 
Rm-Rf 3.14 3.13 3.13 3.14 3.16 3.13 3.13 
 
[0.13]*** [0.13]*** [0.13]*** [0.13]*** [0.13]*** [0.13]*** [0.13]*** 
SMB - - - - 
 
- - 
        HML - - - - 
 
- - 
        Two Weeks Before -197.46 
!      Day Before [89.20]** -453.09 
     Day 
 
[350.96] -671.87 
    Day After  
  
[320.40]** 120.78 
   Two Weeks After 
   
[346.29] -79.15 
  Three Day Window 
    
[90.40] -337.85 
 Five Day Window 
     
[199.61]* -379.64 
       
[150.41]** 
Quarterly Time Trend -159.51 -154.58 -154.77 -148.30 -116.72 -150.12 -147.77 
 
[93.96]* [93.91]* [93.89]* [93.86] [92.00] [93.71] [93.53] 
        Constant 1975.20 1959.85 1961.74 1940.53 1837.50 1948.36 1940.75 
 
[240.76]*** [240.60]*** [240.59]*** [240.38]*** [233.63]*** [240.03]*** [239.45]*** 
Molecule FE Yes Yes Yes Yes Yes Yes Yes 
        Observations 8530 8530 8530 8564 9006 8564 8598 
R-squared 0.1685 0.1682 0.1684 0.168 0.1699 0.1683 0.1688 
Robust standard errors in brackets, clustered by molecule 
     ***significant at 10%; **significant at 5%; *significant at 1% 
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Appendix 2. Fama French Model: Domestic Firms 
 !! !
Table 2.1: Effect of Patent Application Event Date on Firms' Daily Annualized Returns 
Domestic Firms Traded on NYSE or NASDAQ: Fama-French Model 
 
(1) (2) (3) (4) (5) (6) (7) 
Rm-Rf -4.73 -4.75 -4.81 -6.35 -7.89 -6.24 -6.52 
 
[11.92] [11.93] [11.94] [11.92] [11.50] [11.91] [11.89] 
        SMB 14.06 14.18 14.55 14.02 14.14 13.76 14.92 
 
[18.39] [18.40] [18.39] [18.38] [17.79] [18.38] [18.36] 
        HML 5.02 4.75 4.68 2.32 0.83 2.44 2.23 
 
[22.12] [22.13] [22.14] [22.09] [21.53] [22.08] [22.06] 
        Two Weeks Before 78.5 
      Day Before [39.86]** 268.45 
     Day 
 
[158.42]* -20.35 
    Day After 
  
[131.61] 105.5 
   Two Weeks After 
   
[151.33] 39.38 
  Three Day Window 
    
[40.02] 181.81 
 Five Day Window 
     
[86.21] 142.46 
       
[69.49]** 
Overlap 255.53 179.99 181.55 183.13 165.75 181.81 187.71 
 
[101.81]** [94.42]* [94.53]* [94.38]* [92.87]* [94.28] [94.25] 
        Quarterly Time Trend -170.13 -168.6 -168.63 -168.03 -168.94 -168.02 -168.43 
 
[72.06]** [72.09]** [72.08]** [72.11]** [71.98]** [72.11]** [72.05]** 
        Constant 1264.64 1263.68 1264.88 1268.02 1261.43 1267.01 1268.17 
 
[221.60]*** [221.71]*** [221.69]*** [221.77]*** [221.02]*** [221.79]*** [221.57]*** 
Molecule FE Yes Yes Yes Yes Yes Yes Yes 
        Observations 7978 7078 7978 8009 8412 8009 8040 
R-squared 0.0391 0.039 0.0386 0.0385 0.0392 0.0387 0.0389 
Robust standard errors in brackets, clustered by molecule 
     ***significant at 10%; **significant at 5%; *significant at 1% 
! ! ! !
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Table 2.2: Effect of Patent Publication on Firms' Daily Annualized Returns 
 
Domestic Firms Traded on NYSE or NASDAQ: Fama-French Model 
!
(1) (2) (3) (4) (5) (6) (7) 
Rm-Rf 2.63 2.63 2.62 2.63 2.63 2.63 2.63 
 
[0.15]*** [0.15]*** [0.15]*** [0.15]*** [0.14]*** [0.15]*** [0.14]*** 
        SMB -386.65 -386.31 -386.07 -387.73 -399.44 -387.41 -390.22 
 
[40.05]*** [40.04]*** [40.05]*** [40.02]*** [39.28]*** [39.99]*** [39.94]*** 
        HML -285.19 -285.85 -285.94 -283.48 -298.26 -283.69 -280.98 
 
[45.08]*** [45.07]*** [45.06]*** [45.01]*** [44.09]*** [44.99]*** [44.91]*** 
        Two Weeks Before -195.63 
      Day Before [88.68]** -450.14 
     Day 
 
[360.91] -661.3 
    Day After 
  
[316.13]** 127.71 
   Two Weeks After 
   
[344.70] -77.75 
  Three Day Window 
    
[88.96] -330.94 
 Five Day Window 
     
[200.50] -376.83 
       
[149.60]** 
Quarterly Time Trend -322.28 -317.46 -317.6 -311.53 -287.72 -313.3 -311.01 
 
[137.95]** [137.99]** [137.94]** [137.72]** [138.56]** [137.60]** [137.32]** 
        Constant 2270.36 2255.36 2257.16 2237.04 2149.7 2244.77 2236.48 
 
[268.06]*** [267.95]*** [267.89]*** [267.44]*** [261.62]*** [267.18]*** [266.53]*** 
Molecule FE Yes Yes Yes Yes Yes Yes Yes 
        Observations 8523 8523 8523 8557 8999 8557 8591 
R-squared 0.1814 0.1811 0.1813 0.1808 0.1835 0.1811 0.1817 
Robust standard errors in brackets, clustered by molecule 
***significant at 10%; **significant at 5%; *significant at1% 
    !!!! !
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Appendix 3. International Extension 
Table 3.1: Effect of Patent Application on Firms' Daily Annualized Returns 
Domestic and International Firms: CAPM 
 
(1) (2) (3) (4) (5) (6) (7) 
Rm-Rf 121.19 121.24 121.27 121.44 125.44 121.47 121.52 
 
[5.48]*** [5.49]*** [5.49]*** [5.48]*** [5.33]*** [5.48]*** [5.46]*** 
SMB - - - - - - - 
        HML - - - - - - - 
        Two Weeks Before 12.95 
!      Day Before [20.29] 9.59 
     Day 
 
[73.79] -118.85 
    Day After 
  
[55.57]** -37.55 
   Two Weeks After 
   
[71.66] -1.58 
  Three Day Window 
    
[19.65] -49.73 
 Five Day Window 
     
[39.41] -17.69 
       
[32.47} 
Overlap 294.01 294.16 294.26 293.97 27.58 294.06 291.47 
 
[88.02]** [88.01]** [87.99]** [87.74]** [36.01] [87.76]** [87.43]** 
        Quarterly Time Trend 67.99 67.99 67.99 68.18 73.34 68.18 67.24 
 
[88.02]** [34.10]** [34.09]** [33.99]** [33.31]** [34.02]** [33.89]** 
        Constant -22.83 -22.10 -21.60 -23.62 -43.25 -23.18 -20.83 
 
[115.61] [115.60] [115.53] [115.20] [112.27] [115.30] [114.87] 
Molecule FE Yes Yes Yes Yes Yes Yes Yes 
        Observations 10183 10183 10183 102227 10799 10227 10271 
R-squared 0.1075 0.1075 0.1077 0.1074 0.1088 0.1075 0.1077 
Robust standard errors in brackets, clustered by molecule 
     ***significant at 10%; **significant at 5%; *significant at 1% 
    !! !
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Table 3.2: Effect of Patent Application on Firms' Daily Annualized Returns 
Domestic and International Firms: Fama-French Model 
 
(1) (2) (3) (4) (5) (6) (7) 
Rm-Rf 113.46 113.56 113.55 113.81 116.61 113.81 114.00 
 
[6.30]*** [6.30]*** [6.30]*** [6.29]*** [6.11]*** [6.29]*** [6.26]*** 
        SMB -76.47 -76.41 -76.25 -76.65 -78.93 -76.55 -76.60 
 
[10.15]*** [10.15]*** [10.15]*** [10.13]*** [9.95]*** [10.13]*** [10.10]*** 
        HML -15.37 -15.26 -15.38 -14.99 -17.89 -15.06 -14.75 
 
[12.25] [12.25] [12.25] [12.22] [11.87] [12.22] [12.19] 
        Two Weeks Before 14.32 
      Day Before [20.15] 13.13 
     Day 
 
[72.43] -110.57 
    Day After 
  
[56.52]** -30.58 
   Two Weeks After 
   
[71.00] 0.91 
  Three Day Window 
    
[19.54] -43.38 
 Five Day Window 
     
[39.15] -12.63 
       
[32.33] 
Overlap 283.09 283.25 283.38 282.53 15.42 282.62 280.53 
 
[87.63]** [87.62]** [87.60]** [87.33]** [35.87] [87.34]** [87.01]** 
        Quarterly Time Trend 67.53 67.53 67.53 67.60 73.98 67.61 66.89 
 
[33.98]** [33.98]** [33.98]** [33.87]** [33.28]** [33.90]** [33.76]** 
        Constant -18.31 -17.50 -17.04 -18.49 -42.61 -18.11 -16.51 
 
[115.24] [115.22] [115.18] [114.80] [112.15] [114.90] 114.56 
Molecule FE Yes Yes Yes Yes Yes Yes Yes 
        Observations 10183 10183 10183 10227 10799 10227 10271 
R-squared 0.1141 0.114 0.1142 0.114 0.1157 0.1141 0.1143 
Robust standard errors in brackets, clustered by molecule 
    !***significant at 10%; **significant at 5%; *significant at 1% 
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Table 3.3: Effect of Patent Publication Event Date on Firms' Daily Annualized Returns 
 
Domestic and International Firms: CAPM 
 
(1) (2) (3) (4) (5) (6) (7) 
Rm-Rf 2.89 2.89 2.89 2.89 2.90 2.89 2.89 
 
[0.12]*** [0.12]*** [0.12]*** [0.12]*** [0.12]*** [0.12]*** [0.12]*** 
SMB - - - - - - - 
        HML - - - - - - - 
        Two Weeks Before -142.55 
      Day Before [82.25]* 36.54 
     Day 
 
[337.19] -384.85 
    Day After 
  
[302.22] -30.23 
   Two Weeks After 
   
[336.79] -77.35 
  Three Day Window 
    
[82.66] -127.24 
 Five Day Window 
     
[189.50] -211.28 
       
[141.67] 
Quarterly Time 1052.33 1052.33 1052.33 1052.71 1101.82 1052.71 1053.35 
 
[106.18]*** [106.18]*** [106.20]*** [105.98]**** [103.31[*** [105.96]*** [105.62]*** 
        Constant 811.74 802.82 805.14 794.00 674.13 795.81 787.96 
 
[246.95]*** [247.00]*** [246.92]*** [246.54]*** [239.36]*** [246.45]*** [245.72]*** 
Molecule FE Yes Yes Yes Yes Yes Yes Yes 
        Observations 11546 11546 11546 11592 12190 11592 11638 
R-squared 0.1506 0.1504 0.1505 0.1499 0.1513 0.1499 0.1505 
Robust standard errors in brackets, clustered by molecule 
     ***significant at 10%; **significant at 5%; *significant at 1% 
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Table 3.4: Effect of Patent Publication Event Date on Firms' Daily Annualized Returns 
 
Domestic and International Firms: Fama-French Model 
 
(1) (2) (3) (4) (5) (6) (7) 
Rm-Rf 2.58 2.58 2.58 2.58 2.60 2.58 2.58 
 
[0.12]*** [0.12]*** [0.12]*** [0.13]*** [0.13]*** [0.13]*** [0.13]*** 
        SMB -206.69 -206.74 -206.79 -207.61 -220.03 -207.66 -208.69 
 
[33.24]*** [33.25]*** [33.24]*** [35.66]*** [34.87]*** [35.65]*** [35.55]*** 
        HML -216.24 -217.27 -217.74 -212.35 -205.28 -212.53 -211.07 
 
[34.45]*** [34.45]*** [34.45]*** [37.91]*** [37.16]*** [37.91]*** [37.84]*** 
        Two Weeks Before -133.47 
      Day Before [82.02]* 38.98 
     Day 
 
[308.63] -401.84 
    Day After 
  
[308.64] -38.35 
   Two Weeks After 
   
[339.88] -75.03 
  Three Day Window 
    
[82.41] -134.73 
 Five Day Window 
     
[190.68] -217.32 
       
[142.36] 
Quarterly Time 1054.47 1054.46 1054.45 1054.29 1103.13 1054.28 1054.92 
 
[93.23]*** [93.24]*** [93.23]*** [107.98]*** [105.16]*** [107.95]*** [107.61]*** 
        Constant 889.55 881.49 884.07 872.64 752.08 874.58 866.48 
 
[211.42]*** [211.39]*** [211.38]*** [251.75]*** [244.01]*** [251.67]*** [250.92]*** 
Molecule FE Yes Yes Yes Yes Yes Yes Yes 
        Observations 11539 11539 11539 11.585 12183 11585 11631 
R-squared 0.1556 0.1554 0.1556 0.1548 0.1564 0.1549 0.1554 
Robust standard errors in brackets, clustered by molecule 
     ***significant at 10%; **significant at 5%; *significant at 1% 
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Appendix 4. FDA Approval Extension 
Table 4.1: Effect of FDA Drug Approval on Firms' Daily Annualized Returns 
Domestic and International Firms: CAPM 
 
(1) (2) (3) (4) (5) (6) (7) 
Rm-Rf 98.29 98.33 98.13 98.26 99.13 98.31 98.06 
 
[10.90]*** [10.91]*** [10.91]*** [10.90]*** [10.76]*** [10.91]*** [10.90]*** 
        SMB - - - - - - - 
        HML - - - - - - - 
        Two Weeks Before 23.86 
      Day Before [41.70] -123.64 
     Day 
 
[133.74] 89.74 
    Day After 
  
[182.58] -159.58 
   Two Weeks After 
   
[149.58] 40.45 
  Three Day Window 
    
[44.71] -64.75 
 Five Day Window 
     
[93.29] 17.82 
       
[70.98] 
Quarterly Time Trend 189.74 188.27 188.91 182.12 179.06 182.01 177.58 
 
[58.91]** [58.75]*** [58.79]*** [58.73]*** [56.31]*** [58.67]*** [58.49]*** 
        Constant 529.35 534.21 532.08 545.50 537.79 545.84 553.16 
 
[108.04]*** [107.59]*** [107.60]*** [107.56]*** [103.10]*** [107.49]*** [107.12]*** 
Molecule FE Yes Yes Yes Yes Yes Yes Yes 
        Observations 2140 2140 2140 2149 2266 2149 2158 
R-squared 0.2128 0.2129 0.2128 0.2134 0.2091 0.2132 0.2126 
Robust standard errors in brackets, clustered by molecule 
     ***significant at 10%; **significant at 5%; *significant at 1% 
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Table 4.2: Effect of FDA Drug Approval on Event Date on Firms' Daily Annualized Returns 
Domestic and International Firms: Fama-French Model 
 
(1) (2) (3) (4) (5) (6) (7) 
Rm-Rf 113.25 113.50 113.09 113.40 114.18 113.65 113.60 
 
[11.64]*** [11.63]*** [11.64]*** [11.63]*** [11.53]*** [11.65]*** [11.65]*** 
        SMB -26.61 -26.70 -26.48 -26.53 -24.36 -26.50 -26.29 
 
[18.20] [18.20] [18.22] [18.16] [17.98] [18.17] [18.14] 
        HML 70.59 71.78 70.58 71.93 71.20 72.98 74.19 
 
[23.38]*** [23.44]*** [23.39]*** [23.35]*** [23.01]*** [23.38]*** [23.32]*** 
        Two Weeks Before 23.06 
      Day Before [41.70] -151.10 
     Day 
 
[126.79] 81.74 
    Day After 
  
[185.25] -144.86 
   Two Weeks After 
   
[146.22] 40.86 
  Three Day Window 
    
[44.73] -71.93 
 Five Day Window 
     
[92.16] 9.75 
       
[58.32] 
Quarterly Time Trend 191.53 190.06 190.73 183.98 182.14 183.81 179.68 
 
[58.75]*** [58.56]*** [58.62]*** [58.57]*** [56.19]*** [58.53]*** [58.32]*** 
        Constant 521.96 526.82 524.64 183.98 528.78 538.51 545.41 
 
[107.57]*** [107.07}*** [107.13]*** [58.57]*** [102.76]*** [107.05]*** [106.64]*** 
Molecule FE Yes Yes Yes Yes Yes Yes Yes 
        Observations 2140 2140 2140 2149 2266 2149 2158 
R-squared 0.2172 0.2174 0.2172 0.2179 0.2134 0.2187 0.2173 
Robust standard errors in brackets, clustered by molecule 
    !***significant at 10%; **significant at 5%; *significant at 1% 
   !!
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